News

Smoking sped progression of multiple sclerosis


 

References

Patients with multiple sclerosis who continued to smoke after diagnosis had faster disease progression in a population-based, case-control study.

Each additional year of smoking after diagnosis accelerated the time to conversion to secondary progressive multiple sclerosis (SPMS) by 4.7%, and those who smoked continuously each year after diagnosis converted to SPMS an estimated 8 years earlier than did those who quit smoking at diagnosis, according to Ryan Ramanujam, Ph.D., and his colleagues.

©American Heart Association

They analyzed data from a survey of 2,538 MS patients living in Sweden, including 728 who smoked at diagnosis, 1,012 who never had smoked, and 618 who had smoked prior to having been diagnosed. The group of smokers included 118 who stopped smoking during the year after diagnosis, 332 who continued smoking, and 278 who smoked intermittently, meaning they continued smoking for at least 1 year after being diagnosed with MS and were not smoking for at least 1 year after diagnosis.

“This study demonstrates that smoking after MS diagnosis has a negative impact on the progression of the disease, whereas reduced smoking may improve patient quality of life, with more years before the development of SP disease,” the investigators wrote.

“We suggest that these results should be regarded as sufficient to recommend smoking cessation to patients,” they added.

Read the full study in JAMA Neurology (doi: 10.1001/jamaneurol.2015.1788).

klennon@frontlinemedcom.com

Recommended Reading

Thoracic gray matter atrophy linked to MS disability
MDedge Internal Medicine
New drugs saw ‘unprecedented’ spending growth in 2014
MDedge Internal Medicine
Only moderate-quality evidence supports medical cannabinoids
MDedge Internal Medicine
Adherence to MS treatments lower in oral vs. injectable drugs
MDedge Internal Medicine
Optimizing treatment selection in MS often tricky
MDedge Internal Medicine
Abundance of agents adds choice in choosing MS therapy
MDedge Internal Medicine
FDA reports two PML cases in patients with MS treated with fingolimod
MDedge Internal Medicine
FDA investigating risk of gadolinium contrast agent brain deposits
MDedge Internal Medicine
Breastfeeding protects against postpartum MS relapse
MDedge Internal Medicine
Oral methylprednisolone found noninferior to IV steroids for MS relapse
MDedge Internal Medicine